Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn’s and Colitis (IRCC)
Archives of Iranian Medicine · 2024
DOI: 10.34172/aim.2024.27 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Iranian Medicine, 2024. Verfasst von Bahar Saberzadeh-Ardestani und 38 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Crohn Disease, Registries, Colitis, Ulcerative, Phenotype. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Data on the epidemiology of inflammatory bowel disease (IBD) in the Middle East are scarce. We aimed to describe the clinical phenotype, disease course, and medication usage of IBD cases from Iran in the Middle East.
Methods
We conducted a cross-sectional study of registered IBD patients in the Iranian Registry of Crohn’s and Colitis (IRCC) from 2017 until 2022. We collected information on demographic characteristics, past medical history, family history, disease extent and location, extra-intestinal manifestations, IBD medications, and activity using the IBD-control-8 questionnaire and the Manitoba IBD index, admissions history, history of colon cancer, and IBD-related surgeries.
Results
In total, 9746 patients with ulcerative colitis (UC) (n=7793), and Crohn’s disease (CD) (n=1953) were reported. The UC to CD ratio was 3.99. The median age at diagnosis was 29.2 (IQR: 22.6,37.6) and 27.6 (IQR: 20.6,37.6) for patients with UC and CD, respectively. The male-to-female ratio was 1.28 in CD patients. A positive family history was observed in 17.9% of UC patients. The majority of UC patients had pancolitis (47%). Ileocolonic involvement was the most common type of involvement in CD patients (43.7%), and the prevalence of stricturing behavior was 4.6%. A prevalence of 0.3% was observed for colorectal cancer among patients with UC. Moreover,15.2% of UC patients and 38.4% of CD patients had been treated with anti-tumor necrosis factor (anti-TNF).
Conclusion
In this national registry-based study, there are significant differences in some clinical phenotypes such as the prevalence of extra-intestinal manifestations and treatment strategies such as biological use in different geographical locations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Guilan, Iran.
- Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran.
- Golestan Research Center of Gastroenterology, Golestan University of Medical Science, Gorgan, Iran.
- Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- Department of Internal Medicine, School of Medicine, Lung Diseases Research Center, Ardabil, Iran.
ORCID-Profile: Bahar Saberzadeh-Ardestani, Amir Kasaeian, Ali Reza Sima
Zitieren
APA
Saberzadeh-Ardestani, B., Khosravi, A. A., Mansour-Ghanaei, F., Vahedi, H., Baniasadi, N., Seyyedmajidi, M., Parhizkar, B., Hormati, A., Naghshbandi, S. J., Matin, S., Hassan Zadeh, A. A., Taghvaei, T., Bahrami, M., Rafeey, M., Ahadi, M., Vossoughinia, H., Muosavi, H., Gheibi, S., Hosseini-Hemmatabadi, R. S., …, & Sima, A. R. (2024). Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn’s and Colitis (IRCC). Archives of Iranian Medicine. https://doi.org/10.34172/aim.2024.27
Vancouver
Saberzadeh-Ardestani B, Khosravi AA, Mansour-Ghanaei F, Vahedi H, Baniasadi N, Seyyedmajidi M, et al. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn’s and Colitis (IRCC). Archives of Iranian Medicine. 2024. doi:10.34172/aim.2024.27
BibTeX
@article{SaberzadehArdestani2024,
author = {Saberzadeh-Ardestani, Bahar and Khosravi, Amir Ali and Mansour-Ghanaei, Fariborz and Vahedi, Homayoon and Baniasadi, Nadieh and Seyyedmajidi, Mohammadreza and Parhizkar, Baran and Hormati, Ahmad and Naghshbandi, Sayed Jalalledin and Matin, Somaieh and Hassan Zadeh, Amir Abbas and Taghvaei, Tarang and Bahrami, Mohsen and Rafeey, Mandana and Ahadi, Mitra and Vossoughinia, Hassan and Muosavi, Hashem and Gheibi, Shahsanam and Hosseini-Hemmatabadi, Roya-Sadat and Yazdanbod, Abbas and Matinkhah, Saied and Sheikh Esmaeili, Farshad and Fakheri, Hafez and Moosavy, Seyed Hamid and Maleki, Iradj and Nasseri-Moghaddam, Siavosh and Khosravi, Bardia and Farahmand, Fatemeh and Najafi, Mehri and Alimadadi, Hosein and Malekzadeh, Masoud and Anushiravani, Amir and Kasaeian, Amir and Alatab, Sudabeh and Sadeghi, Anahita and Radmard, Amir Reza and Kolahdoozan, Shadi and Rajabi, Zeynab and Sima, Ali Reza},
title = {Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn’s and Colitis (IRCC)},
journal = {Archives of Iranian Medicine},
year = {2024},
doi = {10.34172/aim.2024.27}
}
EUVIMED